Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Skin Neoplasms × sonidegib × Clear all

Phase

Status

Sponsor Class

OTHER 2 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Basal Cell 4 Medulloblastoma 3 Recurrence 2 Basal Cell Nevus Syndrome 2 Thrombocytosis 1 Thrombocythemia, Essential 1 Stomach Neoplasms 1 Skin Neoplasms 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Polycythemia Vera 1 Myeloproliferative Disorders 1 Leukemia, Myeloid, Acute 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia 1 Hemorrhagic Disorders 1 Hematologic Neoplasms 1 Hematologic Diseases 1 Glioblastoma 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Breast Neoplasms 1 Bone Marrow Diseases 1 Blood Platelet Disorders 1 Blood Coagulation Disorders 1 Advanced Solid Tumor 1

Interventions

pembrolizumab 14 Nivolumab 8 cemiplimab 6 Ipilimumab 6 dabrafenib 4 binimetinib 4 Dacarbazine 4 trametinib 3 encorafenib 3 zanolimumab 2 talabostat 2 lifileucel 2 aldesleukin 2 Vemurafenib 2 Tablets 2 Semaxinib 2 Intravital Microscopy 2 Interleukin-2 2 Fluorouracil 2 Drug Therapy 2 Allovectin-7 2 vitespin 1 veliparib 1 varlilumab 1 tozuleristide 1 tin etiopurpurin 1 tilsotolimod 1 spartalizumab 1 sotigalimab 1 sonidegib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01327053 2019-08-28

BOLT

Novartis

Phase 2 Completed

230 enrolled 26 charts

Carcinoma, Basal Cell, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡